KALAMAZOO, Mich.announces today that-- Metabolic Solutions Development Company, LLC (MSDC) will provide an update on the clinical evaluation of MSDC-0160, a first in class mTOT Modulator that is being investigated in an ongoing Phase 2a trial in subjects with mild to moderate dementia due to Alzheimer's disease. The update will be presented at the Alzheimer's Drug Discovery Foundation (ADDF) 13th International Conference on Alzheimer's Drug Discovery in Jersey City, NJ September 10-11, 2012.
MSDC-0160 is a novel insulin sensitizer that modulates mitochondrial metabolism. Growing evidence suggests that loss of mitochondrial function, resulting in a corresponding decline in brain glucose metabolism, could be a contributing cause of Alzheimer's disease.
PR Newswire